C402-CD19-CAR / Exuma Biotech - LARVOL DELTA

C402-001: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Shanghai Exuma Biotechnology Ltd. | Trial completion date: May 2026 ➔ Sep 2029 | Trial primary completion date: Mar 2026 ➔ Apr 2029

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD19 • MYC

C402-001: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Shanghai Exuma Biotechnology Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2